ONCOLOGY Vol 36, Issue 7

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.

Kimberley R. Doucette, MD, MSC; and David H. Vesole, MD, PhD, discuss updates to frontline treatment in multiple myeloma.

Sarah A. Holstein, MD, PhD, reviews updated treatment options for patients with newly diagnosed multiple myeloma.

Sheila Lahijani, MD, FACLP, gives her perspective on the need for psycho-oncologists to help patients during their cancer journeys.

Veronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.

“What is more gratifying than people who are alive in complete remission for years?...The therapeutics are so effective and the symptoms of myeloma can be so rapidly reversed. It’s really gratifying.”

In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, discusses oxaliplatin hypersensitivity reaction in gastrointestinal cancer.